natgillin/translations-raw huggingface dataset:
Ledaga is intended only for use on the skin. 
Zdravilo Ledaga je namenjeno le za uporabo na koži.
If it is not, ask your pharmacist. 
Če ni, se posvetujte s farmacevtom.
A partial response was defined as an at least 50% reduction in the baseline CAILS score. 
Delni odziv je bil opredeljen kot vsaj 50-% zmanjšanje v izhodiščni oceni po CAILS.
If Ledaga gets in your eyes, rinse your eyes right away for at least 15 minutes with large amounts of water, a solution known as “0.9% sodium chloride solution” or an eye-wash solution, and seek medical assistance (including an eye doctor) as soon as possible. 
Če dobite zdravilo Ledaga v oči, si jih takoj vsaj 15 minut izpirajte z velikimi količinami vode, raztopino, imenovano »0,9-% raztopina natrijevega klorida« ali z raztopino za izpiranje oči in čim prej poiščite zdravniško pomoč (tudi okulista).
Exposure of the eyes to chlormethine causes pain, burns, inflammation, photophobia, and blurred vision. 
Izpostavljenost oči klormetinu povzroča bolečino, opekline, vnetje, fotofobijo in zamegljen vid.
Apply your next dose when it is due. 
Naslednji odmerek uporabite,
- Skin cancers (abnormal growth of the cells in the skin) have been reported after application of chlormethine to the skin, although it is not known whether chlormethine causes this. 
- Poročali so o pojavu več oblik kožnega raka (nenormalna rast celic v koži) po nanosu klormetina na kožo, čeprav ni znano, ali jih je povzročil klormetin.
Risks of secondary exposure may include skin reactions, mucosal injury, and skin cancers. 
Tveganja zaradi sekundarne izpostavljenosti lahko vključujejo reakcije na koži, poškodbe sluznice in več oblik kožnega raka.
Pharmacotherapeutic group: Antineoplastic agents, nitrogen mustard analogues, ATC code: L01AA05. 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), analogi dušikovih iperitov, oznaka ATC: L01AA05.
The medicinal product contains propylene glycol and butylhydroxytoluene, which may cause skin irritation (e.g., contact dermatitis). 
Zdravilo vsebuje propilenglikol in butilhidroksitoluen, ki lahko povzročita draženje kože (npr. kontaktni dermatitis).
Efficacy was evaluated in the Efficacy Evaluable (EE) population, which included all 185 patients who were treated for at least 6 months with no major protocol deviations [Table 1], and in the IntentTo-Treat (ITT) population, which included all 260 randomised patients. 
Učinkovitost so ocenili pri populaciji, primerni za oceno učinkovitosti (v nadaljevanju EE - Efficacy Evaluable), ki je vključevala vseh 185 bolnikov, ki so bili zdravljeni vsaj 6 mesecev brez večjih odstopanj od protokola [Preglednica 1] in pri populaciji z namenom zdravljenja (v nadaljevanju ITT
EXP Discard 60 days after defrosting: ../../.... 
EXP Po 60 dneh po odmrzovanju zdravilo zavrzite.
Unopened tube 3 years in the freezer (-15 °C to -25 °C). 
Neodprta tuba 3 leta v zamrzovalniku (od -15 °C do -25 °C).
Patients and caregivers must wash hands after handling Ledaga. 
Bolniki in negovalci si morajo takoj po ravnanju z zdravilom Ledaga umiti roke.
Any unused medicinal product or waste material, including the plastic bag and the nitrile gloves used for application, must be disposed of in accordance with local requirements. 
Neuporabljeno zdravilo ali odpadni material, vključno s plastično vrečko in nitrilnimi rokavicami, uporabljenimi pri nanašanju, je treba zavreči v skladu z lokalnimi predpisi.
In addition, butylhydroxytoluene may also cause irritation to the eyes and mucous membranes (i.e., mouth and nose). 
Butilhidroksitoluen lahko povzroči tudi draženje oči in sluznic (tj. ust in nosu).
Mucosal or eye exposure 
Izpostavljenost sluznic ali oči
Risks of direct skin contact include inflammation of the skin (dermatitis), injury to their eyes, mouth, or nose, and skin cancers. 
Tveganja zaradi neposrednega stika s kožo vključujejo vnetje kože (dermatitis), poškodbe oči, ust ali nosu in oblike kožnega raka.
This is an anti-cancer medicine used on the skin to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL). 
To je zdravilo za zdravljenje raka, ki ga uporabljamo na koži za zdravljenje kožnega T-celičnega limfoma vrste mycosis fungoides (CTLC vrste MF).
There is limited experience of chlormethine in pregnant women. 
Izkušnje z uporabo klormetina pri nosečnicah so omejene.
Tell your doctor if you get any new damaged areas or ulcers on your skin. 
Zdravniku povejte, če na koži opazite kakršne koli nove poškodovane dele ali razjede.
Ledaga contains alcohol and is therefore considered flammable. 
Zdravilo Ledaga vsebuje alkohol in je zato vnetljivo.
• Ledaga should be supplied with a transparent, sealable, child-resistant plastic bag to prevent secondary exposure and contamination when Ledaga is stored in the refrigerator: 
• Zdravilo Ledaga je treba dobaviti v prozorni plastični vrečki, ki jo je mogoče zapreti in je varna za otroke, da se prepreči sekundarna izpostavljenost in onesnaženje ob shranjevanju zdravila v hladilnik:
Adverse reactions reported with Ledaga in an active-controlled trial in patients with MF-type CTCL are shown below. 
Neželeni učinki zdravila Ledaga, o katerih so poročali v preskušanju, nadzorovanem z učinkovino, pri bolnikih s CTLC vrste MF, so navedeni spodaj.
After defrosting, store in a refrigerator. 
Po odmrzovanju shranjujte v hladilniku.
Recommended application instructions should be followed to prevent secondary exposure (see section 4.2). 
Za preprečevanje sekundarne izpostavljenosti je treba upoštevati navodila za nanašanje (glejte poglavje 4.2).
The following instructions should be followed by patients or caregivers when applying Ledaga: 
Bolniki ali negovalci morajo pri nanašanju zdravila Ledaga upoštevati naslednja navodila.
- Apply a thin layer of this medicine to completely dry skin at least 4 hours before or 30 minutes after showering or washing. 
- Tanko plast tega zdravila nanesite na povsem suho kožo vsaj 4 ure pred tuširanjem ali umivanju ali 30 minut po tem.
Therefore, the use of this medicine is not recommended during pregnancy and in women of childbearing age not using contraception. 
Zato uporaba zdravila Ledaga ni priporočljiva pri nosečnicah in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
There are limited data from the use of chlormethine in pregnant women. 
Podatki o uporabi klormetina pri nosečnicah so omejeni.
• Ledaga should be applied immediately or within 30 minutes after removal from the refrigerator. 
• Zdravilo Ledaga je treba nanesti takoj ali v 30 minutah po odvzemu iz hladilnika.
Return it to the refrigerator after each use. 
Po vsaki uporabi ga spravite v hladilnik.
Dispose of the tube, plastic bag and nitrile gloves in accordance with local requirements. 
Tubo, plastično vrečko in nitrilne rokavice je treba zavreči v skladu z lokalnimi predpisi.
Patients were not required to be refractory to or intolerant of prior therapies. 
Odpornost ali intoleranca na predhodna zdravljenja ni bila zahtevana za vključitev v preskušanje.
Store in a refrigerator (+2 °C to +8 °C) at all times, ensuring the tube is in the box inside the childresistant, transparent, sealable, plastic bag. 
Shranjujte v hladilniku (+2 °C do +8 °C) ves čas in poskrbite, da bo tuba spravljena v škatli v prozorni, za otroke varni plastični vrečki, ki jo je mogoče zapreti.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of European Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web portal. 
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
Intravenously administered chlormethine impaired male fertility in rats at a daily dose of ≥ 0.25 mg/kg for 2 weeks. 
Intravensko dajanje klormetina je zmanjšalo plodnost pri podganjih samcih pri 2-tedenskih dnevnih odmerkih ≥ 0,25 mg/kg.
Chlormethine was carcinogenic in rat and mouse carcinogenicity studies after subcutaneous and intravenous administration. 
V študijah kancerogenosti so opazili kancerogene učinke klormetina pri podganah in miših po subkutanem in intravenskem dajanju.
Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients (see section 5.1). 
Zdravilo Ledaga je indicirano za lokalno zdravljenje kožnega T-celičnega limfoma vrste mycosis fungoides (CTLC vrste MF) pri odraslih (glejte poglavje 5.1).
Direct skin contact with Ledaga should be avoided in individuals other than the patient. 
Neposrednemu stiku zdravila Ledaga s kožo se morajo posamezniki, ki niso bolniki, izogniti.
The patient should allow treated areas to dry for 5 to 10 minutes after application before covering with clothing. 
Bolnik mora pustiti, da se deli, namazani z zdravilom, od 5 do 10 minut po nanašanje sušijo, preden jih pokrije z obleko.
Ledaga is not recommended in women of childbearing potential not using contraception. 
Zdravilo Ledaga ni priporočljivo pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
Hypersensitivity reactions, including isolated cases of anaphylaxis, have been reported in the literature after the use of topical formulations of chlormethine (see sections 4.3 and 4.8). 
Preobčutljivost Viri poročajo o preobčutljivostnih reakcijah, vključno s posameznimi primeri anafilaksije, po uporabi zdravil s klormetinom za lokalno uporabo (glejte poglavji 4.3 in 4.8).
- Apply Ledaga immediately or within 30 minutes of removing it from the refrigerator. 
- Zdravilo Ledaga nanesite takoj ali v 30 minutah po tem, ko ste ga vzeli iz hladilnika.
Ledaga contains the active substance chlormethine. 
Zdravilo Ledaga vsebuje učinkovino klormetin.
The median daily usage of Ledaga was 1.8 g. The maximum individual daily usage in the trial was 10.5 g of gel (i.e., 2.1 mg of chlormethine HCl). 
Mediana uporabljena količina zdravila Ledaga na dan je bila 1,8 g. Največja posamezna uporabljena količina zdravila v preskušanju je bila 10,5 g gela (t.j.
Each aluminium tube contains 60 grams of gel and has a white screw cap. 
Vsaka aluminijasta tuba vsebuje 60 gramov gela in ima bel navojni pokrovček.
Do not use a double dose to make up for a forgotten dose. 
Če ste pozabili uporabiti zdravilo Ledaga Ne uporabite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Secondary exposure to Ledaga 
Sekundarna izpostavljenost zdravilu Ledaga
No dedicated animal studies on the effects of chlormethine on female fertility have been reported in the literature. 
Viri ne poročajo o namenskih študijah na živalih o vplivu klormetina na plodnost pri samicah.
MF-type CTCL is a condition in which certain cells of the body's immune system called Tlymphocytes become cancerous and affect the skin. 
CTLC vrste MF je stanje, v katerem določene celice imunskega sistema telesa, imenovane limfociti T,
Similarly, patients who received chlormethine gel 0.04% in a follow-up study (Study 202) had no measurable concentrations of chlormethine or its degradation product (half-mustard) in blood collected 1 hour post-application on Day 1 or after 2, 4, or 6 months of treatment. 
Podobno bolniki, ki so prejemali gel s 0,04 % klormetina v nadaljevalni študiji (študija 202), v krvi, odvzeti 1 uro po nanašanju 1. dne in po 2, 4 ali 6 mesecih zdravljenja, niso imeli merljivih koncentracij klormetina ali njegovega razgradnega produkta (2-kloroetil etil sulfida).
Store and transport frozen. 
Zdravilo shranjujte in prevažajte zamrznjeno.
In animals, adverse effects of chlormethine on male fertility after systemic administration have been documented (see section 5.3). 
Pri živalih so bili dokumentirani neželeni učinki klormetina na plodnost pri samcih po sistemski uporabi (glejte poglavje 5.3).
Ledaga 160 micrograms/g gel 
Ledaga 160 mikrogramov/g gel
• Caregivers must wear disposable nitrile gloves when applying Ledaga to patients. 
• Negovalci morajo pri nanašanju zdravila Ledaga bolnikom nositi nitrilne rokavice za enkratno uporabo.
Ledaga is an alcohol-based product and is flammable. 
Zdravilo Ledaga je na alkoholni osnovi in je vnetljivo.
Propylene glycol and butylhydroxytoluene may also cause skin irritation. 
Tudi propilenglikol in butilhidroksitoluen lahko povzročita draženje kože.
- Do not apply moisturisers or any other skin products (including medicines applied to the skin) for 2 hours before or 2 hours after the daily application of Ledaga. 
- Blažil (vlažil) ali drugih izdelkov za lokalno uporabo (vključno z zdravili, ki se nanašajo na kožo) ne nanašajte na zdravljene dele kože 2 uri pred vsakodnevnem nanosu zdravila Ledaga ali 2 uri po njem.
Reductions in mean CAILS scores were observed as early as at 4 weeks, with further reductions observed with continuing therapy. 
Že pri 4 tednih so opazili zmanjšanje povprečnih ocen po CAILS in nadaljnja zmanjšanja pri nadaljevanju zdravljenja.
Qualifying prior therapies included topical corticosteroids, phototherapy, topical bexarotene, and topical nitrogen mustard. 
Primerna predhodna zdravljenja so vključevala lokalne kortikosteroide, fototerapijo, lokalni beksaroten in lokalni dušikov iperit.
How to use Ledaga 
Kako uporabljati zdravilo Ledaga
Do not apply Ledaga more than once per day. 
Če ste uporabili večji odmerek zdravila Ledaga, kot bi smeli Zdravila Ledaga ne nanesite več kot enkrat na dan.
Your doctor will determine how long you should use Ledaga for and when treatment may be stopped. 
Če ste prenehali uporabljati zdravilo Ledaga Zdravnik bo odločil o tem, kako dolgo morate uporabljati zdravilo Ledaga in kdaj je treba z zdravljenjem prenehati.
- This medicine can cause skin reactions, such as inflammation of your skin (redness and swelling), itching, blisters, ulcers and skin infections (see section 4). 
- Zdravilo lahko povzroči reakcije na koži, na primer vnetje kože (pordelost in oteklino), srbenje, mehurje, razjede in okužbe kože (glejte poglavje 4).
It is not known whether Ledaga passes into breast milk, and there may be a risk that the breast-feeding baby is exposed to Ledaga via contact with the mother's skin. 
Ker ni znano, ali zdravilo Ledaga prehaja v materino mleko, in ker lahko obstaja tveganje za izpostavljenost dojenčka zdravilu Ledaga ob stiku z materino kožo, ni priporočljivo dojiti med jemanjem tega zdravila.
Ask your pharmacist how to throw away used nitrile gloves, the plastic bag and the medicine you no longer use. 
O načinu odstranjevanja nitrilnih rokavic, plastične vrečke in zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
Ledaga is not recommended during pregnancy. 
Uporaba zdravila Ledaga med nosečnostjo ni priporočljiva.
Patients should be assessed during treatment for skin reactions such as dermatitis (e.g., redness, swelling, inflammation), pruritus, blisters, ulceration, and skin infections. 
Bolnike je treba med zdravljenjem pregledati glede reakcij na koži, kot so dermatitis (npr. pordelost, oteklina, vnetje), srbenje, mehurji, razjede in kožne okužbe.
Caregivers must wear nitrile gloves when handling Ledaga. 
Negovalci morajo pri ravnanju z zdravilom Ledaga nositi nitrilne rokavice.
Chlormethine is a type of anti-cancer medicine called an ‘alkylating agent'. 
Klormetin je vrsta zdravila za zdravljenje raka, ki se imenuje
Ledaga should be removed from the refrigerator just prior to application and returned to the refrigerator immediately after each use in its box inside the child-resistant, transparent, sealable, plastic bag. 
Zdravilo Ledaga je treba vzeti iz hladilnika tik pred nanašanjem in ga spraviti nazaj v hladilnik v njegovi škatli v prozorni, za otroke varni plastični vrečki, ki jo je mogoče zapreti, takoj po vsaki uporabi.
Dosing could be suspended or continued at reduced frequency in the case of skin reactions. 
Zdravljenje je bilo v primeru reakcij na koži dovoljeno začasno prekiniti ali nadaljevati z manjšo pogostnostjo.
Store and transport frozen (−15 °C to −25 °C). 
Zdravilo shranjujte in prevažajte zamrznjeno (− 15 °C do − 25 °C).
SWAT Overall Response (CR+PR) 
Celotni odziv po SWAT (PO + DO)
With clean hands, the tube should be placed back into the original box and the box should be placed in the supplied transparent, sealable, plastic bag for storage in the refrigerator. 
Tubo je treba s čistimi rokami vstaviti nazaj v prvotno škatlo, škatlo pa v priloženo prozorno plastično vrečko, ki jo je mogoče zapreti, v kateri zdravilo hranite v hladilniku.
- Keep this leaflet. 
S pokrovčkom prebodite tesnilo.
Skin ulceration and blistering, skin hyperpigmentation 
Pogosti razjede in mehurji na koži, hiperpigmentacija kože
• Emollients (moisturisers) or other topical products may be applied to the treated areas 2 hours before or 2 hours after application of Ledaga. 
• Blažila (vlažila) ali druge lokalne izdelke se sme na zdravljene dele kože nanesti 2 uri pred ali 2 uri po nanosu zdravila Ledaga.
In addition, butylhydroxytoluene has been reported to cause irritation to the eyes and mucous membranes. 
Poročali so tudi, da butilhidroksitoluen povzroča draženje oči in sluznic.
- Keep away from children and contact with food by storing Ledaga in its box and inside the plastic bag. 
- Zdravilo Ledaga hranite nedosegljivo otrokom in ločeno od živil, tako da shranjujete zdravilo Ledaga v njegovi škatli in v plastični vrečki.
CAILS Overall Response (CR+PR) 
Celotni odziv po CAILS (PO + DO)
Patients who received Ledaga in Study 201 had no measurable concentrations of chlormethine in blood collected 1, 3 and 6 hours post-application on Day 1, and at the first month visit. 
Bolniki, ki so prejemali zdravilo Ledaga v študiji 201, po 1, 3 in 6 urah po nanašanju 1. dne in ob obisku čez 1 mesec v odvzeti krvi niso imeli merljivih koncentracij klormetina.
Patients should apply Ledaga to affected areas of the skin. 
Bolniki morajo zdravilo Ledaga nanesti le na prizadete površine kože.
A risk to newborns/infants cannot be excluded due to the potential for topical or systemic exposure of the breast-feeding child to chlormethine through contact with the mother's skin. 
Zaradi možnosti lokalne ali sistemske izpostavljenosti dojenega otroka klormetinu ob stiku z materino kožo tveganja za novorojenčke in dojenčke ni mogoče izključiti.
Dermatitis, skin infections, pruritus 
Zelo pogosti dermatitis, okužbe kože, srbenje
• A patient alert card, sized to be included in Ledaga outer packaging, together with the Patient Information Leaflet (PIL) is provided to all patients and caregivers who are expected to administer and use Ledaga. 
• Vsi bolniki in negovalci, od katerih se pričakuje, da bodo dajali in uporabljali zdravilo Ledaga, prejmejo opozorilno izkaznico za bolnika v velikosti, ki jo je mogoče vstaviti v zunanjo ovojnino zdravila Ledaga skupaj z navodilom za uporabo.
What Ledaga looks like and contents of the pack 
Izgled zdravila Ledaga in vsebina pakiranja
Management of overdose should consist of washing the exposed area with water. 
Ravnanje v primeru prevelikega odmerjanja mora vključevati izpiranje izpostavljenega dela z vodo.
Treatment with Ledaga should be stopped for any grade of skin ulceration or blistering, or moderately severe or severe dermatitis (e.g., marked skin redness with oedema). 
Tanko plast zdravila Ledaga je treba nanesti na prizadete dele kože enkrat na dan. Zdravljenje z zdravilom Ledaga je treba prekiniti v primeru kožnih razjed ali mehurjev katere koli stopnje ali v primeru zmerno hudega ali hudega dermatitisa (npr. izrazite pordelosti kože z edemom).
Contents of the pack and other information 
Shranjevanje zdravila Ledaga Vsebina pakiranja in dodatne informacije
Ledaga is a cytotoxic medicinal product. 
Zdravilo Ledaga je citotoksično zdravilo.
Do not use an opened or unopened tube of Ledaga after 60 days of storage in the refrigerator. 
Po 60-dnevnem shranjevanju v hladilniku odprte ali neodprte tube zdravila Ledaga ne uporabljajte več.
The risk for inflammation of the skin is increased if you apply Ledaga to your face, genital area, anus or skin folds. 
Nevarnost vnetja kože je povečana, če zdravilo Ledaga nanesete na obraz, predel spolovil, danko ali kožne pregibe.
No cases of overdose after cutaneous use of Ledaga were reported during the clinical development programme or post-marketing period. 
V času izvajanja programa razvoja zdravila ali v obdobju trženja niso poročali o primerih prevelikega odmerjanja pri kožni uporabi zdravila Ledaga.
The efficacy and safety of Ledaga were assessed in a randomised, multicentre, observer-blinded, active-controlled, non-inferiority clinical trial (Study 201) of 260 adult patients with Stage IA (141), IB (115), and IIA (4) MF-type CTCL who had received at least one prior skin-directed therapy. 
201) pri 260 odraslih bolnikih s CTLC vrste MF stopnje IA (141), IB (115) in IIA (4), ki so prejeli vsaj eno predhodno zdravljenje kože.
Clear, colourless gel. 
gel Bister brezbarvni gel.
Exposure of mucous membranes such as the oral mucosa or nasal mucosa causes pain, redness, and ulceration, and these may be severe. 
Izpostavljenost sluznic, na primer ustne ali nosne sluznice, zdravilu povzroči bolečino, pordelost in razjede, ki so lahko hude.
If there is accidental skin exposure to Ledaga, caregivers must immediately wash exposed areas thoroughly with soap and water for at least 15 minutes. 
Če pride do nenamernega stika zdravila Ledaga s kožo, mora negovalec takoj izpirati izpostavljene dele z milom in vodo vsaj 15 minut.
What Ledaga is and what it is used for 
Kaj je zdravilo Ledaga in za kaj ga uporabljamo
• irrigation should be performed immediately for at least 15 minutes with copious amounts of water (or sodium chloride 9 mg/ml (0.9%) solution for injection, or a balanced salt ophthalmic irrigating solution may be used if there is eye exposure), and 
Bolnikom je za primer izpostavljenosti katere koli sluznice zdravilu treba svetovati naslednje: • izpostavljeni del je treba takoj vsaj 15 minut izpirati z veliko vode (v primeru izpostavljenosti očesa lahko uporabimo raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje ali uravnoteženo oftalmološko solno raztopino za izpiranje); in
There were no reports of systemic tumours after topical administration of chlormethine. 
Po lokalni uporabi klormetina niso poročali o sistemskih tumorjih.
In a randomised-controlled trial (n=128 exposed to Ledaga for a median duration of 52 weeks), the most frequent adverse reactions to Ledaga were skin related: dermatitis (54.7%; e.g., skin irritation, erythema, rash, urticaria, skin-burning sensation, pain of the skin), pruritus (20.3%), skin infections (11.7%), skin ulceration and blistering (6.3%), and skin hyperpigmentation (5.5%). 
Ledaga je bila 52 tednov) so bili najpogostejši neželeni učinki, povezani s kožo: dermatitis (54,7 %; na primer draženje kože, eritem, izpuščaj, urtikarija, pekoč občutek na koži, bolečina kože), srbenje
Cytotoxic: Handle with caution Flammable: Avoid fire, flame, and smoking 
Vnetljivo: Ne izpostavljajte ognju, plamenom in ne kadite.
- If Ledaga gets in your eyes, it can cause pain, burning, swelling, redness, sensitivity to light, and blurred vision. 
- Če dobite zdravilo Ledaga v oči, lahko povzroči bolečino, opeklino, oteklino, pordelost, občutljivost na svetlobo in zamegljen vid. Lahko povzroči tudi slepoto in hudo trajno poškodbo oči.
Each gram of gel contains chlormethine hydrochloride equivalent to 160 micrograms of chlormethine. 
En gram gela vsebuje klormetinijev klorid v količini, ki ustreza 160 mikrogramom klormetina.
Caregivers who accidentally come into contact with Ledaga must wash the affected area right away for at least 15 minutes. 
Negovalci, ki nenamerno pridejo v stik z zdravilom Ledaga, naj si izpostavljene dele takoj izpirajo z milom in vodo vsaj 15 minut.
The dose is the same for elderly patients (aged 65 years and older) as for younger adult patients (aged 18 years and older). 
Priporočeni odmerek je nanos tanke plasti na prizadete dele kože enkrat na dan. Odmerek je pri starostnikih (starih 65 let in starejših) enak kot pri mlajših odraslih bolnikih (starih vsaj 18 let).